An estimated 87,110 Americans will be diagnosed with invasive melanoma in 2017, 1 and melanoma incidence in the United States is projected to continue to increase at a rate of 3% annually. 2 Mortality rates have risen by 1.5% annually, with a current estimate that 9730 Americans will die from melanoma in 2017. 1 The risk of developing a second primary melanoma ranges from 6% to 12% in various studies [3] [4] [5] and is increased in individuals with nevi, a family history of melanoma, and fair skin. 6 The literature is divided concerning the prognosis of patients with multiple primary melanomas (MPMs) compared to those with a single primary melanoma (SPM). Multiple studies [7] [8] [9] report longer survival in patients with SPM over MPM, while others report shorter [10] [11] [12] [13] [14] or similar [15] [16] [17] survival in SPM compared to MPM patients (Table I) . Several groups have promulgated an ''immunization'' hypothesis, 13, 14 in which the first melanoma primes an immune response that controls the growth and metastasis of subsequent melanomas to explain their findings of longer survival in MPM compared to SPM patients. However, many potential confounding factors may affect survival analysis in patients with MPM. First, patients are more likely to be under closer skin surveillance after having SPM, so MPM are more likely to be detected at an earlier stage and therefore have a better prognosis. Indeed, an evaluation by Bradford et al 18 of 9 cancer registries of the Surveillance, Epidemiology, and End Results (SEER) program from 1973 to 2006 that included 89,515 patients who survived $2 months after their initial melanoma diagnosis found that second melanomas were more likely to be thin compared to the first in MPM patients (depth \1.00 mm in 78% vs. 70%). Similarly, Murali et al 19 reported that subsequent primary melanomas tended to be thinner than the first lesion. Second, in considering survival time starting from the first melanoma diagnosis, patients with MPM may exhibit improved survival as a consequence of living longer, therefore having a greater opportunity to develop additional melanomas. Third, in considering survival time from the most recent diagnosis in patients with MPM, patients with SPM may exhibit longer survival as a consequence of disregarding the survival time between the first and last melanomas.
Utah leads the nation in both melanoma incidence and mortality, 20 and therefore SEER data from Utah were analyzed to address the question of survival time after diagnosis in patients with MPM versus SPM. A novel patient-matching strategy was used that was designed to avoid the potential pitfalls of statistical approaches used in previous studies. After correction for multiple variables, no difference was observed in survival time after first diagnosis between patients with MPM and SPM.
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A total of 887 MPM/SPM pairs were successfully matched and included in the initial analyses. The 2 groups differed significantly by sex, living status, site, stage, and histologic subtype; MPM patients exhibited female predominance, a higher death rate, a proclivity for the face and not the lower extremities, a greater proportion of lentigo maligna subtype and more in situ tumors, while ulceration status was not different (Table II) . The MPM cohort was significantly older and the diagnosis year was later than the SPM cohort. Breslow thickness for the first melanoma was not significantly different between the 2 groups (Table III) . The mean follow-up time was 173.9 months (14.5 years). Unadjusted KaplaneMeier survival analysis comparing matched MPM and SPM patients showed a significant survival disadvantage for MPM patients with a chi-squared valued of 39.29 (P \ .001), as shown in Fig 1. Because multiple factors differed significantly in SPM and MPM matched patients (Tables II and III) , a multivariate Cox proportional hazards model was built with diagnosis age, diagnosis year, sex, invasive, and location (hip and lower extremity, face) as covariates. As shown in Fig 2, this analysis showed no significant survival difference between MPM and matched SPM patients with a hazard ratio (HR) of 1.07 (95% confidence interval [CI] 0.87-1.31; P = .55). We repeated the analysis with only diagnosis year and diagnosis age as covariates (because the former was nearly significant and the latter was significant in the larger model). The HR was 1.08 (95% CI 0.88-1.32; P = .48). A summary of the statistics for the Cox model incorporating multiple variables is shown in Table IV .
Several additional analyses were performed to address different analytical methods used in previous studies. First, to address the possibility that using all patients and survival time from the first diagnosis would agree with previous papers that showed a survival time advantage for MPM patients, the same multivariate analysis used with our matched cases was applied to all patients without matching. The results showed significantly longer survival time for MPM patients (HR 0.632 [95% CI 0.56-0.71]; P\.001), consistent with a longer survival time bias favoring MPM with this approach. Second, all patients were included, and survival time was counted from the second melanoma occurrence for MPM patients (with the restriction that the second diagnosis not be synchronous). Applying the same multivariate Cox regression model, there was a significantly shorter survival time for patients with MPM (HR 1.25 [95% CI 1.08-1.43]; P = .002), consistent with a shorter survival time bias favoring SPM with this approach. In addition, because the MPM cohort contained more in situ melanomas, we restricted the corrected analysis to only invasive melanomas among the matched MPM and SPM patients (SPM, n = 615; MPM, n = 504), and observed no survival difference between MPM and matched SPM patients (HR 0.99 [95% CI 0.76-1.29]; P = .96), suggesting that statistical control for this variable was adequate. Finally, because diagnosis age was the only significant variable in the Cox model (Table IV) , survival analysis was repeated using only this variable, resulting in a nonsignificant difference in survival between the 2 groups (HR 1.11 [95% CI 0.91-1.37]; P = .30). Therefore, age at diagnosis alone explains most of the difference between the unadjusted KaplaneMeier and corrected Cox regression results.
DISCUSSION
Conflicting conclusions regarding differences in survival time for MPM versus SPM patients evident in the literature (Table I) likely stem from different statistical approaches used. Many previous studies [10] [11] [12] [13] [14] [15] measured survival from the time of the first diagnosis, which results in a survival bias toward improved survival for multiple melanomas, because individuals having a greater opportunity to develop additional melanomas have generally lived longer. Indeed, Cox regression analysis performed with our entire MPM and SPM cohorts with no correction or matching showed a significant survival advantage for MPM patients (not shown). In other studies, 16, 17 survival was calculated from the date of the most recently 8 used a delayed-entry method, also known as left truncation, which incorporates the time between the diagnosis of the first and second melanomas, but only time after the second melanoma contributes to the survival analysis.
The approach presented here differed from those discussed above, in that SPM controls were matched by ensuring they survived at least as long as the time between development of first and second melanomas in MPM patients. This method mitigates survival bias seen if SPM patients do not survive long enough to have a second diagnosis, or an opposite survival bias introduced by starting the survival time at the second melanoma diagnosis for MPM patients. After controlling for the multiple differences between the MPM and matched SPM patients, no significant survival difference existed between the groups (Fig 2, Table IV) . These results are consistent with 3 previous studies [15] [16] [17] that used various statistical approaches.
An ''immunization'' hypothesisdin which the first melanoma primes an immune response that controls the growth and metastasis of subsequent melanomasdhas been promulgated by several groups 13, 14 to explain their findings of increased survival in MPM patients. Rather, it seems more likely that patients with a high-risk first melanoma are less likely to survive long enough to have multiple melanomas, and that patients are subjected to more intense surveillance after their first melanoma.
The patients in the Utah MPM cohort were older and female, with a predominance of lentigo maligna subtype on the face, compared to matched SPM patients (Table II) . Most previous studies found that patients with MPM were older males, 7,8,12,14,17,21-23 while 2 studies did not find a sex difference. 11, 12 One report noted that subsequent melanomas were more likely to be located on the head and neck and to be of the lentigo maligna subtype, 23 similar to the Utah findings; however, most previous studies reported that MPM cohorts tend to develop subsequent melanomas in similar distribution sites to their initial melanoma, 13, 16, 21 most commonly on the trunk, [7] [8] [9] 11 and of the superficial spreading subtype followed by the nodular subtype. 7, 10, 16 A limitation of our study, as in all registry-based studies, was that not all information was available for all the patients. Specifically, Breslow depth and ulceration were missing from approximately 85% and 75% of the patients, respectively, because this particular information was not collected by the UCR before 2004. While these factors are major contributors to tumor stage, we did address tumor stage differences between the 2 groups by including in situ versus invasive status in our multivariate analysis. In addition, we did not have melanomaspecific cause of death information and used death from any cause. It seems unlikely that specific cause of death would be different between patients with MPM and SPM.
In summary, no survival difference was observed between MPM and matched SPM patients in the Utah SEER data. Given the increased likelihood of improved surveillance resulting in thinner subsequent melanomas in patients following their initial diagnosis, 18, 19 it is likely that the most important factor in long-term survival for MPM patients is the nature of their first melanoma. These results suggest agreement with Grob 24 that MPM is not a distinct biologic entity, and that long-term prognosis for individuals who survive their first melanoma is more dependent on compliance with self-skin examinations and frequent skin surveillance by an experienced provider to facilitate earlier detection of subsequent melanomas.
In conclusion, using a novel matching approach, a survival difference in patients with MPM versus those with SPM was not observed. 
